Patents by Inventor Amy J. Weiner
Amy J. Weiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090285849Abstract: Novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, as well as novel methods for treating viral infections, including HCV, by administering the compounds and compositions, and novel methods for modulating the immune response by administering the compounds and/or compositions.Type: ApplicationFiled: February 26, 2009Publication date: November 19, 2009Inventors: Paul A. Barsanti, Nathan Brammeier, Anthony Diebes, Liana Marie Lagniton, Simon NG, Zhi Jie Ni, Keith B. Pfister, Casey Philbin, Nicholas Valiante, Allan S. Wagman, Weibo Wang, Amy J. Weiner
-
Patent number: 7521062Abstract: The present invention is directed to novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, novel methods for treating viral infections, including HCV, by administering the compounds, and novel methods for modulating an immune response by administering the compounds.Type: GrantFiled: December 29, 2003Date of Patent: April 21, 2009Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Paul A. Barsanti, Nathan Brammeier, Anthony Diebes, Liana Marie Lagniton, Simon Ng, Zhi-Jie Ni, Keith B. Pfister, Casey Philbin, Nicholas Valiante, Allan S. Wagman, Weibo Wang, Amy J. Weiner
-
Patent number: 7371386Abstract: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.Type: GrantFiled: September 18, 2006Date of Patent: May 13, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Amy J. Weiner, Michael Houghton
-
Patent number: 7252827Abstract: Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). Also disclosed are immunogenic compositions comprising a pharmaceutically acceptable carrier and the fusion protein.Type: GrantFiled: March 25, 1997Date of Patent: August 7, 2007Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Amy J. Weiner, Michael Houghton
-
Patent number: 7135185Abstract: Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a pharmaceutically acceptable carrier, such as a diphtheria toxoid.Type: GrantFiled: May 9, 1995Date of Patent: November 14, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Amy J. Weiner, Michael Houghton
-
Patent number: 7098303Abstract: Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-P he-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a bacterial toxoid, such as a diphtheria toxoid.Type: GrantFiled: May 9, 1995Date of Patent: August 29, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Amy J. Weiner, Michael Houghton
-
Patent number: 6692907Abstract: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.Type: GrantFiled: May 9, 1995Date of Patent: February 17, 2004Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
-
Publication number: 20030017156Abstract: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.Type: ApplicationFiled: May 9, 1995Publication date: January 23, 2003Inventors: AMY J. WEINER, MICHAEL HOUGHTON
-
Patent number: 6303292Abstract: This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositionsType: GrantFiled: March 24, 1998Date of Patent: October 16, 2001Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
-
Patent number: 5968775Abstract: The present invention is directed to extracorporeal cell systems infected with hepatitis C virus (HCV). The present invention also relates to products of such cell systems and their use as vaccines and in immunoassays. Methods whereby HCV-infected extracorporeal cell systems are constructed are included, and various immunoassays to detect HCV antibodies are also presented. The HCV-infected cell systems can be used to screen putative antiviral agents.Type: GrantFiled: May 10, 1995Date of Patent: October 19, 1999Assignee: Chiron CorporationInventors: Michael Houghton, Kathelyn S. Steimer, Amy J. Weiner
-
Patent number: 5856437Abstract: Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.Type: GrantFiled: November 3, 1994Date of Patent: January 5, 1999Assignees: Chiron Corporation, The Director General of the National Institute of Health of JapanInventors: Tatsuo Miyamura, Izumi Saito, Michael Houghton, Amy J. Weiner, Jang Han, Janice A. Kolberg, Tai-An Cha, Bruce D. Irvine
-
Patent number: 5851759Abstract: A heteroduplex tracking assay (HTA), a hybridization based method of determining the genetic relationship between two or more viral genomes, for genotyping HCV is disclosed. The HTA for genotyping HCV was developed using single stranded probes derived form the carboxyl terminus of core and part of the E1 for HCV subtypes 1a, 1b, 2a, 2b, and 3a. HTA is more accurate than RFLP for sub-typing HCV and has potential for identifying new variants and is useful for epidemiological studies.Type: GrantFiled: April 19, 1996Date of Patent: December 22, 1998Assignee: Chiron CorporationInventor: Amy J. Weiner
-
Patent number: 5766845Abstract: This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositionsType: GrantFiled: May 12, 1995Date of Patent: June 16, 1998Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
-
Patent number: 5756312Abstract: This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositions.Type: GrantFiled: April 19, 1994Date of Patent: May 26, 1998Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
-
Patent number: 5728520Abstract: This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositions.Type: GrantFiled: June 6, 1995Date of Patent: March 17, 1998Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
-
Patent number: 5714596Abstract: A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. Reagents for isolating, amplifying, and detecting HCV polynucleotides are provided. These reagents are oligomers comprised of polynucleotide sequences which are capable of forming hybrid structures with HCV target polynucleotide sequences.Type: GrantFiled: March 31, 1993Date of Patent: February 3, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo, Amy J. Weiner, Jang Han, Michael Steven Urdea, Bruce Duncan Irvine, Janice A. Kolberg
-
Patent number: 5712088Abstract: A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. Reagents for isolating, amplifying, and detecting HCV polynucleotides are provided. These reagents are oligomers containing polynucleotide sequences which are capable of forming hybrid structures with HCV target polynucleotide sequences.Type: GrantFiled: May 15, 1995Date of Patent: January 27, 1998Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo, Amy J. Weiner, Jang Han, Michael Steven Urdea, Bruce Duncan Irvine, Janice A. Kolberg
-
Patent number: 5679342Abstract: The present invention is directed to extracorporeal cell systems infected with hepatitis C virus (HCV). The present invention also relates to products of such cell systems and their use as vaccines and in immunoassays. Methods whereby HCV-infected extracorporeal cell systems are constructed are included, and various immunoassays to detect HCV antibodies are also presented. The HCV-infected cell systems can be used to screen putative antiviral agents.Type: GrantFiled: July 27, 1993Date of Patent: October 21, 1997Assignee: Chiron CorporationInventors: Michael Houghton, Kathelyn S. Steimer, Amy J. Weiner
-
Patent number: 5670153Abstract: This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositions.Type: GrantFiled: May 12, 1995Date of Patent: September 23, 1997Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
-
Patent number: 5670152Abstract: This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositionsType: GrantFiled: May 12, 1995Date of Patent: September 23, 1997Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
